Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP680921.RABEa38yg5ZQT97v3c5RVww_ZQ37DCuUnGqnIh0rZeb1o130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP680921.RABEa38yg5ZQT97v3c5RVww_ZQ37DCuUnGqnIh0rZeb1o130_assertion type Assertion NP680921.RABEa38yg5ZQT97v3c5RVww_ZQ37DCuUnGqnIh0rZeb1o130_head.
- NP680921.RABEa38yg5ZQT97v3c5RVww_ZQ37DCuUnGqnIh0rZeb1o130_assertion description "[Furthermore, LC-CD133(+), unlike LC-CD133(-), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP680921.RABEa38yg5ZQT97v3c5RVww_ZQ37DCuUnGqnIh0rZeb1o130_provenance.
- NP680921.RABEa38yg5ZQT97v3c5RVww_ZQ37DCuUnGqnIh0rZeb1o130_assertion evidence source_evidence_literature NP680921.RABEa38yg5ZQT97v3c5RVww_ZQ37DCuUnGqnIh0rZeb1o130_provenance.
- NP680921.RABEa38yg5ZQT97v3c5RVww_ZQ37DCuUnGqnIh0rZeb1o130_assertion SIO_000772 18612434 NP680921.RABEa38yg5ZQT97v3c5RVww_ZQ37DCuUnGqnIh0rZeb1o130_provenance.
- NP680921.RABEa38yg5ZQT97v3c5RVww_ZQ37DCuUnGqnIh0rZeb1o130_assertion wasDerivedFrom befree-2016 NP680921.RABEa38yg5ZQT97v3c5RVww_ZQ37DCuUnGqnIh0rZeb1o130_provenance.
- NP680921.RABEa38yg5ZQT97v3c5RVww_ZQ37DCuUnGqnIh0rZeb1o130_assertion wasGeneratedBy ECO_0000203 NP680921.RABEa38yg5ZQT97v3c5RVww_ZQ37DCuUnGqnIh0rZeb1o130_provenance.